P atient-to-patient variability in drug response is a primary challenge facing development and use of new medicines 1 . A recent approach to understanding such variability involves genotyping coupled with systematic measurement of dose-response across a large and diverse bank ('encyclopedia') of cell lines [2] [3] [4] [5] [6] [7] [8] . In the case of anticancer drugs that block cell proliferation or induce apoptosis 9 , cells are typically exposed to drug over a 10 4 -to 10 5 -fold concentration range, and viability is measured after 72-96 h. Such data is conventionally analyzed from the perspective of IC 50 values (or similar parameters), which are descriptive of the shape of the dose-response curve at its midpoint. However, inspection of doseresponse curves reveals that they differ substantially in shape from one drug to the next and from one cell line to the next. Variability in shape can be quantified by performing a multiparametric analysis using a conventional logistical sigmoidal function
P atient-to-patient variability in drug response is a primary challenge facing development and use of new medicines 1 . A recent approach to understanding such variability involves genotyping coupled with systematic measurement of dose-response across a large and diverse bank ('encyclopedia') of cell lines [2] [3] [4] [5] [6] [7] [8] . In the case of anticancer drugs that block cell proliferation or induce apoptosis 9 , cells are typically exposed to drug over a 10 4 -to 10 5 -fold concentration range, and viability is measured after 72-96 h. Such data is conventionally analyzed from the perspective of IC 50 values (or similar parameters), which are descriptive of the shape of the dose-response curve at its midpoint. However, inspection of doseresponse curves reveals that they differ substantially in shape from one drug to the next and from one cell line to the next. Variability in shape can be quantified by performing a multiparametric analysis using a conventional logistical sigmoidal function where y is a response measure at dose D (typically the experimental data), E 0 and E inf are the top and bottom asymptotes of the response, EC 50 is the concentration at half-maximal effect, and Hill slope (HS) is a slope parameter analogous to the Hill coefficient [10] [11] [12] ( Fig. 1a) . Three values derived from equation (1) are in common use: IC 50 , E max and the area under the dose-response curve (AUC). Although they are not strictly parameters of equation (1), we refer to E max , IC 50 and AUC as 'parameters' for simplicity. EC 50 and IC 50 are the classic measures of drug potency, and E max and E inf are measures of drug efficacy (for anticancer drugs, E max varies between 1 at low doses and 0 at high doses, which corresponds to death of all of the cells). AUC combines potency and efficacy of a drug into a single parameter. AUC values can be compared for a single drug across multiple cell lines exposed to the same range of drug concentrations, but comparison of different drugs is problematic (because the scaling between drugs and dose ranges is generally (1) arbitrary). In the simple case of second-order competitive inhibition, the case considered in most pharmacology textbooks, E 0 = 1, E max = E inf = 0, EC 50 = IC 50 and HS = 1 (Fig. 1a) .
The focus to date on potency [2] [3] [4] [6] [7] [8] 13 ignores the potential impact and biological importance of variation in other parameters, such as the steepness of the dose-response curve or differences in maximum effect (although one recent large-scale study did compute E max and AUC 5 ) . In this paper, we show that different dose-response parameters encode distinct information; some parameters varied systematically with cell line and others with drug. For example, HS and E max were frequently uncorrelated with each other or with half-maximum growth inhibition (GI 50 ), but the parameters varied in a consistent way within a drug class. Because the origins of systematic variation in HS and E max are poorly understood, we performed single-cell analysis of Akt/PI3K/mTOR inhibitors and found that cell-to-cell variability is one explanation for shallow dose-response relationships. Thus, multiparametric analysis yields insight into understudied aspects of drug response that are particularly important near and above the IC 50 value, a concentration range relevant to human patients.
RESULTS

Dose-response parameters vary with compound and cell line
We focused on analysis of previously published data comprising CellTiter-Glo measurement of per-well ATP concentrations (a metric of metabolically active cells) 14 for 64 anticancer drugs (Supplementary Results, Supplementary Table 1 ) and 53 wellcharacterized breast cell lines 3 . Assays were performed before and 3 d after exposure to drugs at nine doses spanning a ~10 5 -fold range (with maximum doses between 0.5 μM and 20 mM depending on potency 3 ). We computed viability as y = N/N C , where the cell number N was measured in the presence of drug, and cell number N C is measured in a no-drug control. As the number of cells present before the start of the experiment was available (N 0 ), we also computed y* = (N -N 0 )/(N C -N 0 ) to yield the GI 50 value for y* = 0.5 (Fig. 1b) . We confirmed key findings using independent dose-response data released through the Cancer Cell Line Project (for which estimates of N 0 are not available) 4 .
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Multiparametric analysis yielded values for EC 50 , IC 50 , GI 50 , HS, E inf , E max and AUC for 2,789 drug-cell line combinations (Supplementary Data Set 1; http://lincs.hms.harvard.edu/db/ datasets/20120/; data filtering described in Online Methods) and revealed substantial differences from one drug and cell line to the next (Fig. 1c) . For example, across cell lines, IC 50 varied ~10 4 -fold, and E max varied from 0 to 0.8 for the microtubule stabilizer docetaxel and HSP90 inhibitor geldanamycin (Fig. 2a,b) , whereas IC 50 varied little for the CDK4/cyclin D1 kinase inhibitor fascaplysin (no more than tenfold), and the maximum effect was high in all cases (E max ~0; Fig. 2c ). In the case of the PI3K inhibitor GSK2126458, the HS was ~1.0, whereas it varied substantially for the polyamine analog CGC-11144 (Fig. 2d,e) .
Association of maximal effect parameters with cell type
We observed that potency, maximal effect and slope were well correlated only for a subset of drugs and cell lines ( Fig. 3a and  Supplementary Fig. 1 TYMS  HDAC  FDPS  DNA cross-linker  Lipoxygenase   ESR1  EGFR  MDM2  ABL/KIT/PDGFR   EGFR  CDK1/2  TOP1  DNA cross-linker  HDAC  MEK  EGFR  DNA replication  AURK/FLT3/ABL/JAK2   DNA cross-linker  AKT  FGFR1/3  AURK  TOP2  CDK1  MTOR  PDGFR/VEGFR/KIT/FLT3   AKT  MTOR  IGF1R  Src  IKK  CDC25  PI3K  HDAC  ELK3  FLT3/JAK2/TrkA   CENPE  EGFR/HER2   PI3K  CHK1  Proteasome   NAE1  Polyamine analogue   PLK1  TOP1  TOP2  CDK4  Proteasome   TOP2  Proteasome   HDAC  HSP90  Proteasome   HSP90  KSP  TUBB  PI3K  TUBB  MTOR  TUBB  TUBB correlated in the case of geldanamycin, they did not for the PI3K inhibitor GSK1059615 (Fig. 3b,c) . IC 50 and E max were generally more highly correlated than GI 50 and E max (for example, for the Src/Abl inhibitor bosutinib: P = 10 −11 versus P = 0.03; Fig. 3d-f) . Thus, parameters we might assume to be interchangeable (for example, IC 50 and GI 50 ) were not, implying that different doseresponse parameters convey different information. To quantify this, we computed the mutual information (MI) 15 between parameter values and either cell or drug type. MI is an information theoretic metric that reveals how informative one variable (for example, IC 50 or E max ) is about a second variable (for example, drug identity or cell type). For example, an MI score of 0 bits for a parameter-drug pair means that they are independent, whereas a score of 1 bit means pairs can be divided into 2 1 = 2 groups having either a low or a high parameter value; similarly, a score of 1.6 bits implies division into 2 1.6 ≈ 3 groups. We estimated the probabilities of observing different values of each dose-response parameter for all of the compounds and cell lines and used MI P values as a statistical measure of significance (this is necessary because nonzero MI values are expected by chance for randomly permuted data). We computed empirical P values by randomly shuffling the doseresponse data (n = 10,000) across all of the cell lines and drugs (further details are in Online Methods).
Parameters quantifying maximum effect (E max and E inf ) showed strong association (P < 10 −4 ) with cell type. For example, all but three of the drugs had an equal or higher value for E max in SKBR3 cells than in SUM159PT cells (Fig. 4a) . IC 50 had a weaker association (P = ~0.05) with cell type and EC 50 , and HS had no significant association (Supplementary Table 2 ). Prevailing 'fractional kill' theory 16, 17 posits that inhibitors of cell-cycle progression (such as paclitaxel) kill only the subset of cells that pass through S or M phases in the presence of drug. Consistent with this, SKBR3 had a substantially longer doubling time than SUM159PT cells (~50 h versus ~20 h and thus lower mitotic and S phase fractions) under the growth conditions used in this study. When we calculated the correlation between dose-response parameters and cell doubling time for all 64 drugs, we observed a strong positive correlation between E max or IC 50 and doubling time, particularly in the case of DNA-damaging agents and microtubule stabilizers ( Fig. 4b and  Supplementary Fig. 2 ). However, when we excluded nominally cell cycle-specific drugs from the analysis (Supplementary Fig. 2 ), DT the association between cell line and both E max and E inf was still statistically significant (P = ~0.02), albeit weaker. Moreover, drugs not classically considered to be inhibitors of cell cycle processes had E max values that correlated with proliferation rate; in the case of bortezomib, the correlation might reflect the role of the proteasome in degradation of cyclins, p21 and p27 (refs. 18-20) , but this is less obvious in the case of drugs such as the HSP90 inhibitor geldanamycin. Also unexpected was the observation that E max values for some cell-cycle inhibitors did not correlate with proliferation rate. For example, the CDK4 inhibitor fascaplysin, the CDC25 inhibitor NSC663284 and the DNA crosslinking agents cisplatin, carboplatin and oxaliplatin all had an E max of ~0 in most cell lines, and any variation was independent of proliferation rate.
Association of E max and hS with drug class
We observed a strong association (P < 10 −4 ) between drug type and potency, efficacy and steepness of the dose-response relationships (Supplementary Table 2 ), meaning that virtually all of the drug pairs could be distinguished on the basis of cell line-dependent variation in one or more parameters. For example, the parameters IC 50 , E max and HS allowed high-confidence (P = 10 −9 to 10 −6 ) discrimination between the pairs of drugs (i) oxamflatin and vorinostat (two HDAC inhibitors), (ii) MG-132 (a proteasome inhibitor) and 17-AAG (an HSP90 inhibitor), and (iii) GSK1059615 (a PI3K inhibitor) and trichostatin A (an HDAC inhibitor) (Fig. 4c-e) . Distinguishability by IC 50 is intuitively obvious and arises when the affinity of a drug for its target is greater than that of a second drug for its target, making the first compound universally more potent.
To better understand distinguishability by parameters other than potency, we grouped drugs into classes on the basis of nominal target or mechanism of action (ignoring potential secondary targets and polypharmacology). We subjected dose-response data for different drug classes to principal component analysis (PCA; Supplementary Fig. 3 ) to rotate the data into a new principal component space in which relationships between dose-response parameters and target could be visualized (independent of cell line). We found that drugs from the same class usually clustered together (Supplementary Fig. 3 ). For example, HDAC inhibitors, proteasome inhibitors and DNA cross-linking drugs had uniformly high maximal effects (E max ~ E inf ~ 0), whereas inhibitors of EGFR and HSP90 had large variation in E max (Fig. 4f) . In the case of HS, mTOR inhibitors had HS ≈ 0 41
. (with a median absolute deviation of 0.11), and for pyrimidine analog or thymidylate synthase inhibitors, HS ≈ 0 65
. (median absolute deviation = 0.15). These values were significantly less than one (P < 1 × 10 −8 ), whereas values of HS to ≈ 1 5 2 6 . . for HDAC and proteasome inhibitors were significantly greater than one (P < 1 × 10 −13 ). Cooperativity is the usual explanation for HS > 1 in classical enzymology and pharmacology, and the steep dose-response curve for proteasome inhibitors is presumed to reflect the presence of seven catalytic subunits in the active enzyme 21 . However, situations in which HS < 1 are less commonly considered, and neither sequential nor independent binding schemes with negative cooperativity result in HS < 1 (ref. 22 ). We Data Set 2) . Among the 40 breast cancer lines in this data set, we found that EGFR inhibitors had significantly higher HS values than PI3K inhibitors (P = 9 × 10 −6 ), and PI3K and AKT inhibitors had higher HS values than mTOR inhibitors (P = ~10 −5 -10 −4 ), whereas HDAC and proteasome inhibitors had significantly higher HS values than all three classes of drugs (P = 10 −3 to 10 −8 ); this was also true when we examined all of the cell lines in the Cancer Cell Line Project data set ( Supplementary  Fig. 4) . We conclude that HS varies in a consistent way with drug class across multiple data sets.
Cell-to-cell variability and shallow dose-response curves
To investigate how a shallow dose-response curve might arise, we focused on drugs inhibiting the PI3K/Akt/mTOR pathway that varied widely in HS and E max values, independent of proliferation rate. As a class, these drugs are undergoing extensive clinical investigation 23 , with more than 300 trials at http://www.ClinicalTrials. gov/. For three compounds with varying HS, we measured target inhibition by immunofluorescence microscopy and cell killing in four breast cell lines (HER2-amplified AU565 and HCC1954 cancer cells, hormone receptor-positive T47D cancer cells and nontransformed MCF10A cells). We probed the effects of the mTOR inhibitor PP242, the PI3K inhibitor GSK1059615 and the dual-specificity mTOR/PI3K inhibitor dactolisib (BEZ235) 24 h after drug exposure in nine-point dose-response assays using antibodies specific for phospho-Akt (p-Akt; at Ser473), p-4EBP1 (at Thr37 and Thr46) and p-S6 (at Ser235 and Ser236) (Fig. 5a) ; p-4EBP1 in particular is generally considered to be the most informative downstream marker of Akt/mTOR/PI3K pathway activity 24, 25 . We also measured amounts of p-Rb (at Ser807 and Ser811) as a surrogate for commitment to the cell cycle 26 . Immunofluorescence microscopy revealed dose-dependent inhibition of p-Akt, p-4EBP1 and p-S6 (Supplementary Fig. 5 ), and viability assays performed 72 h after drug exposure confirmed that HS << 1 for PP242 and dactolisib and HS ~1 for GSK1059615 in all of the cell lines (Supplementary Fig. 6 ). However, we also observed substantial cell-to-cell variability in phosphoprotein staining intensity for cells exposed to the first two drugs (Fig. 5b,c) : the coefficient of variation in p-4EBP1 staining (that is, the s.d. of immunofluorescence signal intensity at the singlecell level divided by the population average) rose for cells treated with PP242 or dactolisib near the IC 50 but not for GSK1059615, which had a low and constant coefficient of variation (Fig. 5d) . Figs. 7-9) . We conclude that a shallow dose-response curve is correlated with high cell-to-cell variability in target inhibition compared to drugs for which HS ~ 1 (in four of four cell lines tested).
We observed similar results for other cell lines (Supplementary
Even at the highest drug concentrations tested (10 μM), a fraction of cells exposed to PP242 but not GSK1059615 retained high p-4EBP1 staining (Fig. 5b,c) . The outlier population in PP242-treated cells with high p-4EBP1 staining had approximately tenfold higher p-Rb staining (P < 10 −50 ) compared to the population with low p-4EBP1, implying that outliers were committed to cell proliferation (Fig. 5e) . The presence of a subset of cells in which the Akt/mTOR/PI3K pathway is insensitive to inhibition by PP242 or dactolisib is a likely explanation for fractional cell killing by these drugs (E max > 0). To determine whether these insensitive cells represent a stable subpopulation or whether they interconvert with sensitive cells, we exposed cultures to two successive drug treatments. We treated MCF10A cells with PP242 for 72 h at a concentration (10 μM) sufficient to induce apoptosis or block proliferation in ~80% of cells. We exchanged the medium and allowed viable cells to recover for 24 h before being exposed a second time to PP242 at a range of nine doses (1 nM to 10 μM) for 72 h. When we compared dose-response curves for the parental (drug-naive) and survivor cell populations (Fig. 5f) , IC 50 values (~1 μM) and HS < 1 were indistinguishable, showing that drug-sensitive cells can arise rapidly from relatively insensitive cells. Thus fractional response did not reflect the presence of a stable subpopulation of drug-insensitive cells but rather showed rapid interconversion between resistant and sensitive states. Cell-to-cell variability in response to PP242 and the shallow doseresponse curve it generates therefore seemed to be stable properties of cell populations.
Variation of cell line responsiveness to each drug class
The value of any single parameter as an effective descriptor of cellular response to a class of drugs should depend on how well the parameter correlates across cell lines. We computed a similarity score for drugs with related nominal targets and treated as significant only those cases in which variation across cell lines was more highly correlated within a drug class than across drugs randomly selected from multiple classes (as scored by P value; Online Methods and Supplementary Fig. 10 ). For example, in the case of the HDAC inhibitors vorinostat and LBH589, E max values had a high similarity score as they varied in a consistent way (as illustrated by MDAMB134VI and T47D cells in Supplementary Fig. 10 ). For EGFR inhibitors, IC 50 values were strongly correlated across cell lines (Pearson's correlation coefficient = 0.90, P < 10 −7 for erlotinib and AG1478), but E max was not correlated (Pearson's correlation coefficient ~0.4, P ~ 0.1). The reasons for these differences are not known, but we speculate that erlotinib and AG1478 exert their effects on the same target (EGFR) near their IC 50 values but have additional and different targets at high drug concentrations where E max values become relevant. When comparing drugs, we must therefore account for the fact that different parameters are informative for different drug classes.
An alternative way to approach this problem is to determine the ability of a single parameter to accurately describe a full doseresponse relationship. We computed the correlation between the response estimated from a single parameter of a conventional logistic curve and the measured response. In the case of the canonical dose response having E max = 0, EC 50 = IC 50 and HS = 1, the correlation would be perfect across all drug concentrations. We performed the analysis across the range of doses for all of the drugs and cell lines by scoring the P values of the correlation coefficient. We observed that E max was best correlated with actual response at high doses, IC 50 and AUC were best at intermediate doses (near the median IC 50 for all of the cell lines), and EC 50 or GI 50 were best at low doses (near the IC 50 for the most sensitive cell line). These findings are depicted as continuous plots for 17-AAG, carboplatin and doxorubicin and for the full data set as a set of optimal parameters for each dose range (Fig. 6a,b) . A priori, we are most interested in parameters that are informative at clinically relevant concentration ranges. We can estimate these ranges from the plasma concentration (C max ) at the maximal tolerated dose; in general, effective drugs are ones in which C max /IC 50  1 (Supplementary Table 3) . Incorporating this information, we saw that, in the clinical range, the most informative parameter varied with drug (for example, AUC for 17-AAG, IC 50 for carboplatin and E max for doxorubicin).
DISCUSSION
To date, systematic analysis of large-scale dose-response data has concentrated on the closely related parameters EC 50 , IC 50 and GI 50 , thereby making the implicit assumption that potency at the midpoint of the dose-response curve is the most important difference between drugs or between sensitive and resistant cells [2] [3] [4] [6] [7] [8] 13 . In this paper, we examined variation in features other than potency such as E max , HS and AUC. For many drugs, IC 50 (or GI 50 ), E max and HS did not correlate, and MI analysis revealed systematic variation with both drug and cell type: in the latter case, differences in cell proliferation rates emerged as a probable explanation, particularly for variation in E max and drugs that target cell cycle processes. This is consistent with extensive evidence that inhibitors of DNA synthesis or mitotic spindle assembly exert their effects (at least in culture) only when cells transit S or M phase. However, not all of the cell cycle inhibitors have E max > 0. For example, inhibitors of CDK4 (fascaplysin), CDK phosphatase CDC25 (NSC663284) and the DNA cross-linking agents cisplatin, carboplatin and oxaliplatin had E max ~ 0 for the vast majority of cell lines tested. Moreover, observed variation in E max was independent of proliferation rate. Conversely, we observed a significant (MI P < 0.05) association between E max and proliferation rate for drugs that are not typically considered to be cell cycle inhibitors, including the HSP90 inhibitor geldanamycin and the proteasome inhibitor bortezomib (although the latter drug does affect degradation of cyclins and other cell cycle regulators). Further analysis of killing by cell cycle inhibitors whose effects do and do not correlate with proliferation is likely to be informative, particularly in the case of clinically important cytotoxic chemotherapeutics with similar targets.
For drugs that showed large variation in multiple, uncorrelated dose-response parameters, the question of which one is most informative arose. AUC, a parameter that combines potency and efficacy into a single measure, was robust as a response metric when the goal was to compare a single drug across cell lines exposed to identical dose ranges. Other parameters could be used with multiple drugs and concentration ranges, but their value varied with dose: E max was more informative at high compared to low doses, and the opposite was true of IC 50 and GI 50 . With anticancer drugs, it is typical to aim for a maximum serum dose (C max ) near the maximum tolerated dose, and drugs for which C max /IC 50  1 are preferred clinically. During development of a new drug, reducing IC 50 is obviously an important goal, but when the aim is to understand variability in patient responses to an existing drug, our data suggest that it is likely to be more informative to focus on E max and HS.
In many cases, the origins of variation in dose-response parameters remain to be determined. Association with drug class or target is confounded by polypharmacology, which almost certainly affects the shape of dose-response curves at high drug concentrations (particularly with phenotypic measures of response). Future analysis of different compounds having the same nominal target should help resolve this issue. Differences in the physicochemistry of drug-target interaction (for example, association rate, polar surface area and so on) are potential sources of variation in parameters other than IC 50 , and it should be possible to tackle this with sophisticated cheminformatic analysis 27, 28 . However, in this paper, we focused on understanding the origins of fractional maximum effect and shallow dose-response curves.
We found that the HS was particularly high for drugs such as proteasome and HDAC inhibitors (for example, bortezomib and LBH589), whereas inhibitors of the Akt/PI3K/mTOR pathway had low and variable HS, particularly drugs such as PP242, temsirolimus, everolimus and rapamycin. Positive cooperativity provides a framework for understanding steep dose-response relationships (HS > 1) 10, 22 , but even negative cooperativity should not result in HS < 1. By comparing the dose-dependent inhibition of proteins in the Akt/PI3K/mTOR pathway following exposure of cells to drugs with HS ~ 1 or HS < 1, we found that shallow dose response was associated with high cell-to-cell variability in target inhibition. Moreover, when we recovered and expanded cells that were initially insensitive to a drug such as PP242 and then reassayed drug response several days later, we observed the same shallow dose-response curve and fractional killing at high dose as in the original cell population. This implies that HS < 1 is a stable property of a cell population and that states of drug sensitivity and insensitivity interconvert on the timescale of days. We and others have observed similar effects in receptor-mediated cell death 29, 30 , activation of immune response 31 or sensitivity to chemotherapeutic drugs 32 and ascribed them to stochastic fluctuation in the amounts or activities of intracellular signaling proteins. In principle, the molecules of a drug target present in any single cell could show a canonical HS = 1 dose-response curve, but fluctuation in target amount, activity or interaction with other proteins 33 might cause the IC 50 value to vary from cell to cell, giving rise to a shallow dose-response curve at the population level.
It is notable that mTOR inhibitors had some of the lowest values for HS and that this pathway is also subject to complex feedback regulation. Moreover, what seem to be static differences from one cell to the next in the fixed-time point experiments in this article NATURE ChEmICAL bIOLOgy dOI: 10.1038/nCHeMBIO.1337 paper are likely to arise from temporal fluctuations that are asynchronous across the population. Mutations and nongenetic factors that generate dose-response curves with HS < 1 and E max > 0 are likely to be important clinically: the incremental therapeutic benefit of getting closer and closer to the maximum tolerated dose will be less for a drug with a shallow rather than steep dose-response curve. Studies on dose-response relationships for antiviral drugs have also concluded that variation in HS is important for assessing drug sensitivity and resistance 21, 34 . Attempts to identify new drugs or effective combination therapies might therefore focus on steepening the dose-response relationship and increasing maximum effect, not just decreasing IC 50 . 
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Dose-response curve fitting. We obtained dose-response curves for the 72-h effect of 64 drugs, including both targeted agents and cytotoxic therapeutics on the viability and growth of 53 breast cell lines using previously published data 3 (http://lincs.hms.harvard.edu/db/datasets/20120/). Briefly, we fitted triplicate nine-dose (1:5 serial dilution) data to the logistical sigmoidal model (equation (1); constraints: E 0 = 1 and 0 < HS < 4) using nonlinear least-squares regression performed in GraphPad Prism 6. We excluded 'no response' data defined as data that (i) showed higher statistical quality (based on extrasum-of-squares F test) when fitted to a constant model (y = E inf ) in comparison with the sigmoidal model or (ii) their sigmoidal fitted curve Hill slopes were < 0.25, from the analysis. We also removed data fitted to the sigmoidal model with R 2 < 0.70 from the analysis. Approximately 82% of the 64 × 53 possible combinations of drug-cell line data passed all of filtering requirements and were used in all of the analyses.
We estimated doubling times for cell lines from the ratio of cell numbers at 72 h to 0 h for untreated cells. We estimated different dose-response parameters for each individual curve, including EC 50 , IC 50 , GI 50 , Hill slope (HS), E inf and E max . In the case of IC 50 and GI 50 , when the dose-response data were of high quality, but IC 50 or GI 50 values were not reached, we set the values to the largest concentration tested. Additionally, we calculated a parameter AUC representing the area under the relative viability curve, defined as the sum of measured responses (relative viability) at all tested concentrations of the drug. Hence, AUC = 9 corresponds to an inactive compound, whereas smaller AUC values correspond to higher drug activities in inhibiting cell proliferation and/or inducing cell death. When multiple replicates of data on a drug or cell line combination are available, we used medians of the dose-response parameters estimated across replicates for the statistical analysis.
Association of different dose-response parameters with anticancer drugs and breast cell lines. We assessed associations of each of the key dose-response parameters, log 10 (EC 50 ), log 10 (IC 50 ), Hill slope, E max and E inf , with the set of n = 64 drugs (or n = 38 when excluding cell cycle inhibitors) and the set of m = 53 cell lines using mutual information 15 . A rationale for using mutual information is to capture differences not only in the median (or mean) but also in the variance of dose-response parameters across different cell lines and compounds. We discretized each of the dose-response parameters X into q equally spaced bins, where q = floor [log 2 (no. of samples) + 1] = 12 (or q = 11 when excluding cell cycle inhibitors) 35 . We defined matrix N for each individual dose-response parameter so that N i,j was the number of cell lines whose dose-response parameter values for the ith drug (1 ≤ i ≤ n) lay within the jth bin of X d , the discretized form of X (1 ≤ j ≤ q). We computed the empirical mutual information between X d and the drugs as where
Mutual information scores of zero correspond to independence of the doseresponse parameters from the tested drugs and cell lines, whereas larger values imply strong association, indicating that knowing a dose-response parameter value gives important information about drugs and cell lines to which the parameter is expected to belong. To evaluate the significance of the mutual information scores, we computed empirical mutual information P values by randomly shuffling (10,000 trials) the dose-response parameter values among all of the tested cell lines and drugs.
Statistical analysis of drug response profiles. We evaluated differences in values of a dose-response parameter between different drugs or different cell lines by using a nonparametric Wilcoxon signed rank test. We evaluated differences in dose-response parameters between different drug classes that might contain different numbers of drugs by using a nonparametric Mann-Whitney U-test. We corrected P values from the Mann-Whitney U-test and Pearson correlation analyses using the Benjamini-Hochberg method 36 for multiple independent comparisons and the Bonferroni-Holm correction 37 for other comparisons.
To measure the extent of similarity among drug-response profiles, we used pairwise Pearson correlation scores by considering for each drug its pattern of dose-response parameter values across the cell lines. We computed the similarity score for a selected group of N drugs (for example, drugs within a class defined on the basis of drug target or mechanism of action) as the average similarity between all possible pairs of drugs belonging to the selected group (average correlation) divided by the expected average similarity between all possible pairs of drugs in a randomly selected set of N drugs. To evaluate the significance of the similarity score for a selected group of N drugs (SS), we computed empirical P values by permutation test; for a number of n = 10,000 trials, we sampled a random set of N drugs from the whole set of 64 drugs and computed the similarity score for that set (SS*). For a given SS ≥ 0, we counted the number of times (r) that SS ≤ SS* across the n permutation trials. We then computed the empirical P value as (r + 1)/(n + 1).
Principal component analysis. Principal component analysis (PCA)
is an efficient way to simplify and present multidimensional data into fewer dimensions 38 . For example, each drug in our analysis can be described by 53 IC 50 values, 53 HS values and 53 E max values corresponding to the parameters for growth inhibition assays for 53 breast cell lines. Therefore, each drug can be represented by a vector pointing into 53 × 3 = 159 dimensional space that depicts its effect on the cell line panel. Because it is not possible to visualize 159-dimensional graphs, we used PCA to recognize the 159-dimensional relationships into three primary dimensions (i.e., principal components) that can be plotted on a graph. These principal components are a linear combination of the original dimensions. We organized dose-response parameters into a matrix with 64 rows (corresponding to drugs) and 159 columns (corresponding to dose-response parameters IC 50 , HS and E max for all cell lines), took the logarithm of parameters, imputed missing values from the nearest-neighbor row (the closest row in Euclidean distance), normalized each parameter value via calculating the Z score for each parameter across the 64 drugs and performed PCA. We can discuss the results of PCA in terms of component scores (the transformed variable values corresponding to a particular data point) and loadings (the weight by which each normalized original variable should be multiplied to get the component score).
Cell lines and reagents. We obtained AU565, HCC1954 and T47D breast cancer cell lines and MCF10A mammary epithelial cells from the American Type Culture Collection (ATCC). We cultured AU565 and HCC1954 cells in RPMI 1640 (ATCC) supplemented with 10% FBS (FBS), T47D cells in RPMI 1640 supplemented with 10% FBS and insulin (0.2 U/ml) and MCF10A cells in DMEM/F12 (Invitrogen) supplemented with 5% horse serum, EGF (20 ng/ml), insulin (10 μg/ml), hydrocortisone (0.5 μg/ml) and cholera toxin (100 ng/ml). We added penicillin (50 U/ml) and streptomycin (50 μg/ml) to all growth medium.
We purchased dactolisib (BEZ235), GSK1059615 and PP242 from Selleck Chemicals. All of the compounds were at least 97% pure, as evaluated by HPLC and MS analysis. All of the compounds were dissolved in DMSO as 10-mM stock solutions. For dose-response experiments, we plated cells in two replicates at 7,000 cells per well in 96-well plates (Corning) in full growth medium for 24 h and then treated them with nine doses in serial dilutions (10 −10 to 10 −5 M) of each compound for 6 h, 24 h and 72 h.
